
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is a performance beauty company that offers innovative and differentiated medical aesthetic products, with an established brand and 14% market share in the U.S. The company's cash-pay model and focus on millennials, combined with the recent launch of new products and plans for international expansion, position it for future growth. Its diverse product portfolio and strategic pricing flexibility mitigate potential risks and drive potential revenue growth, supporting our Buy rating and $13 price target.
Bears say
Evolus is facing a difficult market environment, with slowdowns in the last three major downturns and a recent weakening of the market for injectable neurotoxins. Despite its differentiated go-to-market strategy and established market share, the company's financials are concerning, with cash on hand and access to debt being the only saving grace. The recent launch of new products may provide some upside, but with weak market conditions and new competitors, the company's ability to achieve its long-term financial targets is uncertain.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares